Details

Autor(en) / Beteiligte

• Ma, Rui
• Zhu, Dan-Ping
• Zhang, Xiao-Hui
• Xu, Lan-Ping
• Wang, Yu
• Mo, Xiao-Dong
• Lv, Meng
• Zhang, Yuan-Yuan
• Cheng, Yi-Fei
• Yan, Chen-Hua
• Chen, Yu-Hong
• Chen, Yao
• Wang, Jing-Zhi
• Wang, Feng-Rong
• Han, Ting-Ting
• Kong, Jun
• Wang, Zhi-Dong
• Han, Wei
• Chen, Huan
• Chang, Ying-Jun
• He, Yun
• Xu, Zheng-Li
• Zheng, Feng-Mei
• Fu, Hai-Xia
• Liu, Kai-Yan
• Huang, Xiao-Jun
• Sun, Yu-Qian

Titel

Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience

Ist Teil von

• Bone marrow transplantation (Basingstoke), 2024-07, Vol.59 (7), p.991-996

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2024

Quelle

Nexis

Beschreibungen/Notizen

• Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. However, there are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different donor after conditioning with fludarabine and cyclophosphamide). Herein, we report updated outcomes in 30 patients using this method. The median time of the second transplantation was 96.5 (33-215) days after the first transplantation. Except for one patient who died at +19d and before engraftment, neutrophil engraftments were achieved in all patients at 11 (8-24) days, while platelet engraftments were achieved in 22 (75.8%) patients at 17.5 (9-140) days. The 1-year OS and DFS were 60% and 53.3%, and CIR and TRM was 6.7% and 33.3%, respectively. Compared with the historical group, neutrophil engraftment (100% versus 58.5%, p < 0.001) and platelet engraftment (75.8% versus 32.3%, p < 0.001) were better in the novel regimen group, and OS was also improved (60.0% versus 26.4%, p = 0.011). In conclusion, salvage haploidentical transplantation from a different donor using the novel regimen represents a promising option to rescue patients with graft failure after the first haploidentical transplantation.